Brokerages Set Context Therapeutics Inc. (NASDAQ:CNTX) Target Price at $5.40

Context Therapeutics Inc. (NASDAQ:CNTX) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $5.40.

Several research firms have recently weighed in on CNTX. Wall Street Zen upgraded shares of Context Therapeutics to a “sell” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, October 8th. Cantor Fitzgerald assumed coverage on Context Therapeutics in a research report on Thursday, October 2nd. They set an “overweight” rating for the company. HC Wainwright raised their price objective on Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Guggenheim initiated coverage on Context Therapeutics in a research report on Thursday, September 18th. They set a “buy” rating and a $5.00 target price on the stock.

Context Therapeutics Price Performance

Context Therapeutics stock opened at $1.13 on Friday. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $1.65. The stock has a market capitalization of $103.82 million, a PE ratio of -4.71 and a beta of 1.94. The firm has a 50 day simple moving average of $1.15 and a 200-day simple moving average of $0.88.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). On average, analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CNTX. Vanguard Group Inc. boosted its position in shares of Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after buying an additional 134,449 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Context Therapeutics in the third quarter worth approximately $100,000. Finally, Clear Harbor Asset Management LLC grew its position in Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after purchasing an additional 35,000 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.